Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose Oxytocin in Children With Autism and Intellectual Disability
2024-513436-14-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Autism Spectrum Disorder (ASD) and intellectual disability (ID) comparing Oxytocin nasal spray with Placebo nasal spray (2 arms). Primary endpoints: Brief Observation of Social Communication Change (BOSCC), Autism Treatment Evaluation Checklist (ATEC) and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)intellectual disability (ID)
Beyond the preview
Go deeper on 2024-513436-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513436-14-00.